Clinical trials: Proliferation
Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in PDR.
- Trial name
- NCT00563043
- Testing
- PASCAL laser treatment
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Squamous Cell Carcinoma of the Head and Neck
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
This is an open label pilot study evaluating the pharmacodynamics and safety of single agent olaparib administered at 300mg bid (twice a day) for 14 days orally in patients with human papillomavirus (HPV) -positive and human…
- Trial name
- NCT02686008
- Testing
- Olaparib
- Sponsor
- Yale University
Non-Proliferative Diabetic Retinopathy
To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR
This study is planned to evaluate the efficacy and safety of combination therapy with B55R1 and B55R2 compared to B55R1 monotherapy in patients with non-proliferative diabetic retinopathy (NPDR).
- Trial name
- NCT07230184
- Testing
- B55R1 and B55R2
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- AJU Pharm Co., Ltd.
Gaucher Disease, Hepatitis C
Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C
Study objectives: Investigate the anti-HCV response in patients with Gaucher disease(GD) Define the potential role of high levels of Glucocerebroside in the immune system Study hypothesis: High levels of Glucocerebroside can be…
- Trial name
- NCT01274208
- Where
- 2 sites in Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Proliferative Diabetic Retinopathy
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
Proliferative diabetic retinopathy (PDR) is the most common causes of irreversible blindness in diabetic retinopathy (DR).Intravitreal injection of anti-VEGF drugs is a good adjunct to vitreous surgery for severe PDR.
- Trial name
- NCT05408416
- Testing
- preoperative group and intraoperative group
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Peking University People's Hospital
Gastrointestinal Dysmotility
Enteric Neural Precursor Cells (ENPC) in the Human Gut
The study aim is to acquire human tissues to (a) understand the structure and organization of the human Enteric Nervous System; (b) perform a molecular transcriptomic profile of individual cells residing in the human gut; (c)…
- Trial name
- NCT04880538
- Testing
- Endoscopic procedure
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Graft-Versus-Host Disease(GVHD), Anemia Due to Disturbance of Proliferation and/or Differentiation of Hematopoietic Stem Cells
CliniMACS® CD34+ Reagent System for Expanded Access Use
CliniMACs is an investigational device used to select and enrich stem cells. The device will select the stem cells with CD34+ protein.
- Conditions
- Graft-Versus-Host Disease(GVHD), Anemia Due to Disturbance of Proliferation and/or Differentiation of Hematopoietic Stem Cells, Graft Failure, Delayed Graft Function
- Trial name
- NCT02026934
- Testing
- CliniMACS CD34 Reagent System
- Where
- United States
- Sponsor
- Joseph Antin
Patients With Proliferative Diabetic Retinopathy Who Have Active Fibrovascular Proliferation
Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling
Internal limiting membrane peeling in diabetic vitrectomy will help prevent postoperative epiretinal membrane formation
- Trial name
- NCT00556244
- Testing
- ILM peeling
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Anemia, Myelodysplastic Syndromes
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of improvement of anemia in patients diagnosed with low- or intermediate-1 risk…
- Conditions
- Anemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low to Intermediate-1 MDS
- Trial name
- NCT01736683
- Testing
- Sotatercept
- Where
- 20 sites in United States, France
- Volunteers
- 74 people
- Sponsor
- Merck Sharp & Dohme LLC
Moderate Non-proliferative Diabetic Retinopathy
The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy
The purpose of this study is to evaluate the role of alpha lipoic acid in patients who have moderate non-proliferative diabetic retinopathy.
- Trial name
- ALA-TPD (NCT01880372)
- Testing
- Alpha Lipoic Acid
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Ferris State University
Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248157
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Prevention Trial in Subjects at High Risk for Breast Cancer
The primary objective of the proposed trial is to assess. The efficacy and the safety of a daily administration of nimesulide or simvastatin to change the expression of a large set of tissue and circulating surrogate endpoint…
- Trial name
- NCT01500577
- Testing
- nimesulide, Simvastatin
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Ovarian Cancer, Peritoneal Cavity Cancer
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Giving colony-stimulating factors, such as G-CSF help stem cells move from the patient's bone marrow to the blood so they can be collected and stored.
- Trial name
- NCT00652691
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Proliferative Diabetic Retinopathy
Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.
The used of reduced fluence parameters for panretinal photocoagulation decreases pain as perceived by the patient, compared to traditional parameters.
- Trial name
- NCT00802269
- Testing
- Retinal laser photocoagulation
- Where
- Mexico
- Volunteers
- 25 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.
- Trial name
- NCT00664183
- Testing
- Vitreosolve
- Where
- 17 sites in United States, India
- Volunteers
- 400 people
- Sponsor
- Vitreoretinal Technologies, Inc.
High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
To evaluate the safety and determine the efficacy of PRP monotherapy or combination therapy (pegaptanib 0.3 mg plus PRP) in patients with Type I or Type II diabetes mellitus and with high risk proliferative diabetic retinopathy.
- Conditions
- High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I, Diabetes Mellitus Type II
- Trial name
- NCT01281098
- Testing
- Panretinal Photocoagulation (PRP), Intravitreous injection of pegaptanib
- Where
- Portugal
- Volunteers
- 22 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Non-Proliferative Diabetic Retinopathy
Intravitreal and Intracameral DEX in NPDR
To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy
- Trial name
- NCT06951087
- Testing
- Dexamethasone sodium phosphate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Affiliated Hospital of Nantong University
Non-Proliferative Diabetic Retinopathy
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
The goal of this clinical trial is to learn if drug TNTL works to treat non-proliferative diabetic retinopathy in adults. It will also learn about the safety of drug TNTL. The main questions it aims to answer are: 1.
- Trial name
- TNTL (NCT06817265)
- Testing
- TNTL, TNTL simulation preparation
- Where
- 30 sites in China
- Volunteers
- 360 people
- Sponsor
- Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Melanoma, Non-small Cell Lung Cancer
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
- Trial name
- NCT04596033
- Testing
- GEN-011, IL-2, Fludarabine
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Genocea Biosciences, Inc.
Rhegmatogenous Retinal Detachment
Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy
Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients; to prove the percentage of PVR-IC decides the risk of serious…
- Trial name
- NCT04520789
- Testing
- RPE cell collection and single cell heterogeneity study, Postoperative intervention, Conventional Surgery for Retinal Detachment
- Volunteers
- 60 people
- Sponsor
- Shanghai 10th People's Hospital